Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Shilpa Medicare Ltd. Share Price
Day's Range
Day's Range
Low
₹409.00
High
₹425.95
Price Summary
| Previous Close | ₹418.70 |
|---|---|
| Day's Range | ₹409.00 - ₹425.95 |
| Open | ₹410.65 |
| 52 Week Range | ₹259.50 - ₹500.00 |
| Volume | 4,20,018 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,764.73 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.12 |
| Price/Earning (TTM) | 54.58 |
| TTM EPS (₹) | 7.67 |
| P/E Ratio | 82.81 |
| Book Value(₹) | 3.29 |
| PAT Margin (%) | 6.09 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 6.94 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1253.87 | 3097.87 |
| Expenses | N/A | N/A |
| PBT | 248.58 | 380.9 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 156.47 | 269.37 |
About Shilpa Medicare Ltd.
| Founded | 1987 |
|---|---|
| Managing Director | Vishnukant Bhutada |
| NSE Symbol | SHILPAMED |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,37,662.69 | 1,824.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,75,692.42 | 6,618.20 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,43,908.69 | 4,252.05 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,11,261.29 | 7,727.50 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,07,826.86 | 1,334.85 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,07,499.64 | 1,287.95 | 1,129.40 - 1,129.40 |
| Lupin Ltd. | 1,07,489.16 | 2,350.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 98,438.74 | 1,011.45 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 93,323.97 | 2,266.80 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 90,727.09 | 901.65 | 835.50 - 835.50 |
No Records Found
Latest News
Shilpa Medicare informs about appointment of COO
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the aforesaid SEBI Circular, Shilpa Medicare has informed that Dr. Vellaian Karuppiah has been appointed as the Chief Operating Officer (COO) - Formulations (Senior Managerial Personnel) of the Company with effect from 23 April 2026. His appointment has been duly approved by the Nomination and Remuneration Committee. The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated 30th January 2026, are enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Shilpa Medicare informs about press release
Shilpa Medicare informs about updates
Albert David informs about board meeting
In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Albert David has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the May 12, 2026, to: 1. Consider, approve and take on record the Audited Financial Results of the Company for the Fourth Quarter and Financial Year ended on March 31, 2026. 2. Consider recommendation of Final Dividend, if any, for the Financial Year ended on March 31, 2026. The trading window for dealing in equity shares of the Company is already closed from April 1, 2026, and shall open 48 hours post declaration of the above results. The above notice is also being made available on the website of the Company at www.albertdavidindia.com.
The above information is a part of company’s filings submitted to BSE.
Rainbow Children's Medicare informs about updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Shilpa Medicare Ltd. is ₹418.70 as of 2026-05-04.
The market capitalisation of Shilpa Medicare Ltd. is ₹8,189.01 as of 2026-05-04.
The 1-year return of Shilpa Medicare Ltd. is 0.00% as of 2026-05-04.
The P/E ratio of Shilpa Medicare Ltd. is 82.81 as of 2026-05-05.
The 52-week high and low of Shilpa Medicare Ltd. are ₹500.00 and ₹259.50, respectively, as of 2026-05-04.
People Also Ask
Shilpa Medicare Ltd. establishes partnerships by operating as a highly specialised Contract Development and Manufacturing Organisation (CDMO). The firm collaborates with global pharma companies to manufacture complex active pharmaceutical ingredients (APIs) and specialised oncology formulations for international markets.
Shilpa Medicare Ltd. offers highly specialised pharmaceutical products, primarily focusing on oncology and niche therapeutic drugs. The company operates multiple USFDA-approved manufacturing facilities dedicated to producing complex APIs, high-potency formulations, and advanced biologics.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
